ALZN
Alzamend Neuro Inc
$
2.960
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.0099
Open
2.980
VWAP
2.97
Vol
249.60K
Mkt Cap
8.57M
Low
2.920
Amount
740.60K
EV/EBITDA(TTM)
--
Total Shares
7.38M
EV
4.62M
EV/OCF(TTM)
--
P/S(TTM)
--
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q2
FY2026Q1
--
--
-3.870
+126.32%
--
--
-3.690
+2.5%
--
--
-3.690
-67.2%
Estimates Revision
The market is revising No Change the revenue expectations for Alzamend Neuro, Inc. (ALZN) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -50.32%.
EPS Estimates for FY2026
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-50.32%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Alzamend Neuro Inc (ALZN.O) is -0.27, compared to its 5-year average forward P/E of -22.02. For a more detailed relative valuation and DCF analysis to assess Alzamend Neuro Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-22.02
Current PE
-0.27
Overvalued PE
32.46
Undervalued PE
-76.51
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-7.40
Current EV/EBITDA
-0.41
Overvalued EV/EBITDA
7.93
Undervalued EV/EBITDA
-22.73
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q3
YoY :
-61.00%
-1.04M
Operating Profit
FY2025Q3
YoY :
-60.96%
-1.04M
Net Income after Tax
FY2025Q3
YoY :
-94.96%
-0.19
EPS - Diluted
FY2025Q3
YoY :
-29.93%
-1.42M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 3189.56% over the last month.
Sold
0-3
Months
210.0K
USD
4
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
7
25.9K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
206.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 3189.56% over the last month.
Sold
0-3
Months
210.0K
USD
4
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
7
25.9K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
206.0
USD
Months
ALZN News & Events
Events Timeline
2025-07-23 (ET)
2025-07-23
08:06:53
Alzamend Neuro reports FY25 net cash provided by financing activities of $10.4M
2025-06-16 (ET)
2025-06-16
08:08:42
Alzamend Neuro announces final closing of $5M private placement
2025-05-29 (ET)
2025-05-29
08:07:07
Alzamend Neuro doses first patient in Phase II study of AL001
Sign Up For More Events
Sign Up For More Events
News
8.5
06-16NewsfilterAlzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
9.0
05-29BenzingaAlzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone
4.5
05-29BenzingaCrude Oil Falls Over 1%; Best Buy Reports Downbeat Results
Sign Up For More News
People Also Watch
ADIL
Adial Pharmaceuticals Inc
0.514
USD
+7.08%
FATBB
FAT Brands Inc
2.700
USD
-1.10%
BKYI
BIO-Key International Inc
0.833
USD
+0.36%
SRM
TRON Inc
0
USD
+34.76%
LGCB
Linkage Global Inc
2.700
USD
0.00%
CHNR
China Natural Resources Inc
3.750
USD
-0.53%
GNPX
Genprex Inc
0.272
USD
-4.55%
FORD
Forward Industries Inc
10.060
USD
+4.68%
SPRC
Scisparc Ltd
7.260
USD
-5.59%
PBM
Psyence Biomedical Ltd
11.500
USD
+15.12%
FAQ
What is Alzamend Neuro Inc (ALZN) stock price today?
The current price of ALZN is 2.96 USD — it has decreased -1 % in the last trading day.
What is Alzamend Neuro Inc (ALZN)'s business?
What is the price predicton of ALZN Stock?
What is Alzamend Neuro Inc (ALZN)'s revenue for the last quarter?
What is Alzamend Neuro Inc (ALZN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Alzamend Neuro Inc (ALZN)'s fundamentals?
How many employees does Alzamend Neuro Inc (ALZN). have?